However, according to The Cancer Genome Atlas (TCGA) database, nine of the 371 HCC patients (2.4%) with upregulated MYCN mRNA expression but not the seven patients (1.9%) with MYCN amplification had a dramatically worse prognosis (Figure S1A). This evidence concerns the gene MYCN and hepatocellular carcinoma.